Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize...

Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and
Commercialize DNA Methylation Cancer Tests

ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a
licensing agreement with Abbott, which marks the achievement of significant
milestones within their on-going Research and Option Agreement for development
and commercialization of Rubicon MethylPlex(TM) methylation detection
technology for the diagnosis and prognosis of cancer.

Under the terms of the agreement Abbott receives a non-exclusive license to
MethylPlex for in vitro molecular diagnostics to detect the presence or risk
of prostate, bladder and colon cancer for screening and non-screening
indications. Abbott also obtains a non-exclusive license for non-screening
applications with other diseases and options to colon cancer biomarkers
developed in collaboration with Rubicon.

"This license is a significant validation of the MethylPlex technology as an
effective, simple, automatable method for detecting cancer using DNA
methylation in patient plasma," said James Koziarz, Acting President and CEO
of Rubicon. Mr. Koziarz went on to say, "The collaboration between Rubicon
and Abbott has been very productive with both parties making significant
contributions towards development and commercialization of IVD products that
employ MethylPlex biomarkers and assays. We look forward to continuing our
joint efforts under our collaboration and developing leading edge products."

About Rubicon Genomics, Inc.
Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that
has developed and commercialized reagents and kits to increase the analytical
and clinical performance of analytical platforms including Q-PCR, microarrays,
and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and
MethylPlex(TM) products achieve unbiased amplification and standardization of
total DNA, total RNA, and methylated DNA. By producing highly pure DNA of
uniform concentration and molecular weight these products increase the
sensitivity, specificity, and reproducibility of conventional instrumentation
in research and diagnostic applications, including analysis of single cells,
formalin-fixed tissue and plasma. Rubicon sells GenomePlex and TransPlex
services to the research market, as well as licenses and kits to the clinical
markets, including pre-implantation and prenatal testing, and diagnostic
manufacturing. GenomePlex and TransPlex kits are sold to the research-only
market by Sigma-Aldrich. In addition, Rubicon partners with diagnostic
companies using MethylPlex to discover and validate novel DNA methylation
biomarkers, and to co-develop cancer diagnostic tests. For more information
and to contact Rubicon, please visit www.rubicongenomics.com.

SOURCE Rubicon Genomics, Inc.

John Langmore of Rubicon Genomics, Inc., +1-734-368-1705,
langmore@rubicongenomics.com